Edition:
United States

Fortress Biotech Inc (FBIO.OQ)

FBIO.OQ on NASDAQ Stock Exchange Capital Market

1.62USD
3:00pm EDT
Change (% chg)

$-0.04 (-2.11%)
Prev Close
$1.66
Open
$1.67
Day's High
$1.67
Day's Low
$1.58
Volume
12,086
Avg. Vol
34,804
52-wk High
$5.53
52-wk Low
$1.41

Latest Key Developments (Source: Significant Developments)

Fortress Biotech Q2 Loss Per Share $0.50
Thursday, 9 Aug 2018 04:05pm EDT 

Fortress Biotech Inc ::FORTRESS BIOTECH REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q2 LOSS PER SHARE $0.50.Q2 REVENUE $63.8 MILLION VERSUS $50.7 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.59 -- THOMSON REUTERS I/B/E/S.  Full Article

Mustang Bio Q1 Loss Per Share $0.24
Monday, 14 May 2018 05:30pm EDT 

May 14 (Reuters) - Mustang Bio ::MUSTANG BIO REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.MUSTANG BIO - Q1 LOSS PER SHARE $0.24.  Full Article

Fortress Biotech Reports FY Revenue Of $187.6 Mln
Friday, 16 Mar 2018 07:30am EDT 

March 16 (Reuters) - Fortress Biotech Inc ::FORTRESS BIOTECH REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.SAYS FY REVENUE $187.6 MILLION.‍AS OF DECEMBER 31, 2017, CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS, CASH DEPOSITS, RESTRICTED CASH TOTALED $168.3 MILLION​.  Full Article

Avenue Says Dosed First Patient in Phase 3 Safety Trial of IV Tramadol
Tuesday, 2 Jan 2018 08:00am EST 

Jan 2 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 3 SAFETY TRIAL OF INTRAVENOUS TRAMADOL FOR THE MANAGEMENT OF POSTOPERATIVE PAIN.AVENUE THERAPEUTICS INC - COMPANY EXPECTS TO INITIATE A SECOND PHASE 3 TRIAL IN PATIENTS FOLLOWING ABDOMINOPLASTY SURGERY IN Q3 OF 2018.AVENUE THERAPEUTICS- EVALUATING IV TRAMADOL IN PHASE 3 TRIAL IN PATIENTS FOLLOWING BUNIONECTOMY SURGERY, EXPECTS TO REPORT TOPLINE DATA IN Q2,2018.  Full Article

Mustang Bio's Mb-102 Car T Therapy Achieves Complete Response In Phase 1 Clinical Trial
Monday, 11 Dec 2017 04:30pm EST 

Dec 11 (Reuters) - Fortress Biotech Inc ::MUSTANG BIO'S MB-102 (CD123 CAR) CAR T THERAPY ACHIEVES COMPLETE RESPONSE IN ACUTE MYELOID LEUKEMIA AND BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM IN PHASE 1 CLINICAL TRIAL.MUSTANG BIO - INVESTIGATORS FOUND INFUSIONS OF MB-102 ARE SAFE AND WELL TOLERATED.MUSTANG BIO - CAR T THERAPY IS SAFE, WELL TOLERATED.  Full Article

Mustang Bio reports Q3 loss per share of $0.27
Tuesday, 14 Nov 2017 08:30am EST 

Nov 14 (Reuters) - Mustang Bio::Mustang Bio reports third quarter 2017 financial results and recent corporate highlights.Q3 loss per share $0.27.  Full Article

Fortress Biotech posts Q3 loss per share $0.67
Thursday, 9 Nov 2017 04:05pm EST 

Nov 9 (Reuters) - Fortress Biotech Inc :Fortress Biotech reports third quarter 2017 financial results and recent corporate highlights.Q3 loss per share $0.67.Q3 revenue $46.9 million versus $1.0 million.  Full Article

Fortress Biotech announces pricing of series a preferred stock offering
Tuesday, 7 Nov 2017 08:30am EST 

Nov 7 (Reuters) - Fortress Biotech Inc :Fortress Biotech Inc announces pricing of series a preferred stock offering.Fortress Biotech Inc - ‍priced offering of one million shares of its 9.375 pct series a cumulative redeemable perpetual preferred stock at $25.00 per share​.  Full Article

Fortress Biotech proposes public offering of Series A preferred stock
Wednesday, 1 Nov 2017 09:20am EDT 

Nov 1 (Reuters) - Fortress Biotech Inc :Fortress Biotech announces proposed public offering of Series A preferred stock.  Full Article

Mustang Bio enters lease agreement for production of Car T therapies
Monday, 30 Oct 2017 07:30am EDT 

Oct 30 (Reuters) - Fortress Biotech Inc :Entered lease agreement for manufacturing facility to support clinical development, commercialization of co's Car T product candidates​.Facility is expected to be operational for production of personalized Car T therapies in 2018​.Has entered into a lease agreement with UMASS Medicine Science Park in Worcester, Massachusetts​.  Full Article

BRIEF-Fortress Biotech Reports Q1 Loss Per Share $0.49

* FORTRESS BIOTECH REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS